Clinical Trials · NCT05706506
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 152
- Start date
- Mar 2023
- Locations
- 32 sites, United States
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)